Introduction
This report summarises national passive surveillance data for adverse events following immunisation (AEFI) reported to the Therapeutic Goods Administration (TGA) by 28 February 2018. The report focuses on AEFI reported for vaccines administered during 2017 and trends in AEFI reporting over the 18-year period 1 January 2000 -31 December 2017.
An adverse event following immunisation is defined as any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine. 1 The adverse event may be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease. 1 Thus, AEFI may be caused by a vaccine(s) or may be coincidental. Adverse events may also include conditions that occur following the incorrect handling and/or administration of a vaccine(s). The post-marketing surveillance of AEFI is particularly important to detect signals of rare, late onset or unexpected events, which are difficult to detect in pre-registration vaccine trials.
Reports summarising national AEFI surveillance data have been published regularly since 2003. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Trends in reported AEFI are heavily influenced by changes to vaccine funding and availability provided through the National Immunisation Program (NIP). These changes impact on the interpretation of trend data and have been described in detail in reports published since 2003. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Table 1 shows the chronological listing of the changes. • November 2016: Zoster vaccine (Zostavax®) provided free for people aged 70 years under the NIP with a five year catch-up program for people aged 71-79 years.
• March 2016 -NIP-funded booster dose of the diphtheria, tetanus, and acellular pertussis-containing vaccine (DTPa) at 18 months of age. This was earlier recommended from March 2015.
• April 2015: New immunisation requirements for family assistance payments were announced by the federal government. With the 'No Jab, No Pay' policy coming into effect as of 1 January 2016, only parents of children (aged less than 20 years) who are 'fully immunised' or on a recognised catchup schedule will continue to receive the Child Care Benefit, Child Care Rebate, and/ or the Family Tax Benefit Part A end-of-year supplement. Children with medical contraindications or natural immunity for certain diseases continue to be exempt from the requirements; however, conscientious objection is no longer a valid exemption from immunisation requirements.
• From March through June 2015: the dTpa vaccine for women during the third trimester of pregnancy was funded by New South Wales, South Australia, Western Australia, the Australian Capital Territory, Victoria and Tasmania. The Northern Territory had funded it since September 2013 and Queensland since July 2014.
• In March 2015: annual seasonal influenza vaccine was funded for Aboriginal and Torres Strait Islander children aged 6 months to less than 5 years.
To assist readers, at the end of this report there is a glossary of the abbreviations of the vaccines referred to in this report.
Methods
AEFI are notified to the TGA by state and territory health departments, health professionals, vaccine companies and members of the public. 16 All reports are assessed using internationally consistent criteria 17 and entered into the Australian Adverse Events Management System (AEMS) database. Reports are used in data mining and signal detection activities conducted by the TGA. Where there is insufficient information in a report to determine causality for a serious adverse event the TGA will attempt to contact the reporter on up to three occasions to elicit further information.
AEFI data
De-identified information on all AEFI reported to the TGA from 1 January 2000 to 31 December 2017, and stored in the AEMS database, were released to the National Centre for Immunisation Research and Surveillance (NCIRS) in March 2018. Readers are referred to previous AEFI surveillance reports for description of the surveillance system. 
Study definitions of AEFI outcomes and reactions
AEFI were defined as 'serious' or 'non-serious' based on information in the report sent to the TGA and criteria similar to those used by the World Health Organization 17 and the US Vaccine Adverse Events Reporting System. 18 In this report, an adverse event is defined as "serious" if it meets one or more of the following criteria: (1) results in death; (2) is life-threatening; (3) requires inpatient hospitalisation or prolongation of existing hospitalisation; (4) results in persistent or significant disability/incapacity; (5) is a congenital anomaly/birth defect; or (6) is a medically important event or reaction.
Typically, each record lists several reaction terms that are symptoms, signs and/or diagnoses that have been coded by TGA staff from the reporter's description into standardised terms using the Medical Dictionary for Regulatory Activities (MedDRA). In reports published previously, in order to analyse the data, MedDRA coding terms were grouped to create a set of reaction categories that were broadly analogous to the reactions listed in previous editions of the Australian Immunisation Handbook. 16, 21 However, the methodological framework of reporting of adverse events was revised in 2014 and an amended format for AEFI analyses using MedDRA preferred terms (PTs) was adopted. 22 For this report, MedDRA PTs are used for analysis. Grouping of reactions using PTs is more comparable with data from other countries and is internationally accepted. [23] [24] [25] In conjunction with the currently used national vaccine-specific reporting form, 26 the use of PTs allow better reflection of post-marketing surveillance data on vaccines in Australia.
Data analysis
All data analyses were performed using SAS software version 9.4.
27 Average annual population-based reporting rates were calculated for each state and territory and by age group using 2017 population estimates obtained from the Australian Bureau of Statistics. 28 All rates are presented as average annual rates per 100,000 population. Reporting rates per 100,000 administered doses were estimated where information was available on the number of doses administered. This was done for vaccines funded through the NIP for children aged <7 years. The number of administered doses of each of the vaccines given to this age group was obtained from the Australian Immunisation Register (AIR), a national population-based register. 29 From 30 September 2016, the Australian Childhood Immunisation Register (ACIR) became the AIR), recording vaccinations given to people of all ages in Australia. 30 In the future, as reporting in older age groups (≥7 years) becomes more complete, denominator data on vaccine doses administered in older age groups will be analysed for the purposes of AEFI reporting.
Notes on interpretation
Caution is required when interpreting the data presented in this report. Due to reporting delays and late onset of some AEFI, the data are considered preliminary, particularly for the fourth quarter of 2017. Data published in previous reports may differ from those presented in this report for the same period because this report has been updated to include delayed notifications to the TGA that were not included in prior publications. Data can also differ because records may be updated and recoded when follow up information is received or when vaccinespecific analyses are conducted.
The information collated in the AEMS database is intended primarily for signal detection and hypothesis generation. While reporting rates can be estimated using appropriate denominators, they cannot be interpreted as incidence rates due to under-reporting and biased reporting of suspected events, and the variable quality and completeness of information provided in individual notifications. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 31 It is important to note that this report is based on vaccine information and MedDRA PTs collated in the AEMS database and not on comprehensive clinical notes or case reviews. The reported symptoms, signs and diagnoses in each AEFI record in the AEMS database are temporally associated with vaccination but are not necessarily causally associated with a vaccine or vaccines.
Comparison with online Database of Adverse Events Notifications (DAEN)
In August 2012, the TGA made available to the public on its website a searchable database, the Database of Adverse Event Notifications (DAEN) that contains reports of adverse event reports for medicines and vaccines. 32 The data in this report have not been downloaded from DAEN. This report uses data sent to NCIRS by the TGA and includes more detailed information than provided by the DAEN. The numbers published in this report may differ from the numbers in the DAEN database, due to different dates of data extraction and amendment to reports where further information has become available. In addition, this report provides several features that are not available from the DAEN database, including long-term trends and population and dose-based reporting rates, described in the context of changes in vaccine policy and utilisation, and reporting practices.
Results
The AEMS database included a total of 3,878 records where the date of vaccination (or onset of adverse event, if vaccination date was not reported) was between 1 January and 31 December 2017. Of these, 56.6% (2, 195) were female, 41.8% (1,622) male and 1.6% (61) missing data on sex. Also, 1.8% (70) were reported in Aboriginal and Torres Strait Islander people.
In 2017, approximately 80% (3,100) of AEFI were reported to the TGA via states and territories, while the rest were reported directly to the TGA by healthcare professionals (9.5%; n=368), members of the public (6.5%; n=253), vaccine companies (2.5%; n=97) and hospitals (1.5%; n=60).
Reporting trends
The overall AEFI reporting rate for 2017 was 15.8 per 100,000 population compared with 14.1 per 100,000 in 2016. The highest rate was observed in 2010 (17.4 per 100,000), predominantly due to reports in children following vaccination with the pandemic and 2010 seasonal trivalent influenza vaccines. 12 Most reported events in 2017 (from all reporter types) were of a non-serious nature, similar to previous years ( Figure 1) . 10, 11 Figures 2, 3 and 4 demonstrate marked variations in reporting levels in all age groups associated with changes to the NIP. The increase in reports in 2017 was predominantly associated with the introduction of the state/territory funded meningococcal ACWY conjugate vaccine in schools for grade 10-12 students and also an increase in AEFI reports following zoster vaccination in the elderly (Figure 4) . Annual reporting rate per 100,000 population excluding members of the public Note: For reports where the date of vaccination was not recorded, the date of onset or date event was reported to TGA was used as a proxy for vaccination date.
number of AEFI notifications for vaccinations administered in the first half of the year ( Figure  1 ). This corresponds to the months when influenza vaccine is given and older Australians may be more likely to be given 23vPPV in conjunction with the influenza vaccine (March to June). However, more AEFI reports following influenza vaccination were received in each of the last five years than years prior to 2009 (pre-pandemic era) (Figure 4 ).
Age distribution
The highest age-specific AEFI reporting rate per 100,000 population occurred in children aged 1 to <2 years, the age group that received the booster dose of DTPa at 18 months of age ( Figure 5 ). Compared with 2016, AEFI reporting rates remained relatively stable across most age groups, however, there were increases observed in children aged 1 to <2 years, 7 to <20 years and adults aged 65 years and older ( Figure 5 ).
There were no significant differences in reporting rates per 100,000 doses for most individual vaccines in 2017 compared to 2016, noting the new additions to the NIP schedule namely zoster and state/territory-based meningococcal ACWY vaccination programs (Table 2) .
For children <7 years of age, AEFI reporting rates for varicella, Hib and MenC vaccines should be interpreted with caution since monovalent versions of these vaccines were replaced by combination vaccines in July 2013 and hence very few doses of monovalent vaccine were recorded in 2017. 0  50  100  150  200  250  300  350  400  450  500  550  600  650  700  750  800  850  900  950  1000  1050  1100  1150  1200  1250 b Number of AEFI records in which the vaccine was coded as 'suspected' of causal involvement in the reported adverse event and the vaccination was administered between 1 January and 31 December 2017. More than one vaccine may be coded as 'suspected' if several were administered at the same time. 
Geographical distribution
Population-based reporting patterns varied between states and territories during 2017 (Table 3) . Reporting rates were not significantly different (with overlapping confidence intervals) across most jurisdictions in 2017 compared with 2016. 33 However, significant increases were observed in some states and territories that had state-funded vaccination programs for meningococcal disease (South Australia, Victoria and Tasmania).
Vaccines
There were 3,878 AEFI records reported in 2017 (Table 4 ). There were moderate variations in the proportions with outcomes defined as 'serious', although these remained generally low as in previous years.
The vaccine most frequently reported as associated with AEFI was seasonal influenza vaccine (574 records; 14.8% of 2017 records) followed by hexavalent DTPa-IPV-HepB-Hib (n=445; 11.5%), 13vPCV (n=425, 11.0%), rotavirus vaccine (n=410; 10.6%), meningococcal B (n=383; 9.9%), DTPa-IPV (n=380; n=9.8%) and DTPa (n=376; n=9.7%) ( Table 4 ).
For zoster vaccine (funded on NIP from November 2016), there were 342 AEFI reports in 2017 with only 3.5% (12) of these coded as serious.
Reactions
The most frequently reported adverse events in 2017 were injection site reactions (ISRs) (n=1,319; 34% of total), pyrexia (n=669; 17%), rash (n=592; 15%), vomiting (n=304; 8%), pain (n=280; 7%) and headache (n=275; 7%) (Table 5, Figure 6 ). Adverse events of particular interest included anaphylaxis (n=59; 1.5%) hypotonichyporesponsive episode (n=55; 1.4%), convulsions (n=36; 0.9%), intussusception (n=9; 0.2%) and Guillain-Barré Syndrome (n=4; 0.1%) ( Table 5 ). b AEFI records where only one vaccine was suspected of causal involvement in a reported adverse event.
c 'Serious' is defined in the Methods section. d Includes only AEFI records where an age or date of birth has been reported. e Percentages are calculated for the number of AEFI records where the vaccine was suspected of causal involvement in the event b Selected reported adverse events reported during Jan-Dec 2017. Note: for injection site reaction, rash and convulsions, PT's were grouped as described below. c AEFI records where only one adverse event was reported. d 'Serious' outcomes are defined in the Methods section. e Includes only AEFI records where an age or date of birth has been reported f Percentages relate to the number of AEFI records in which the specific adverse event was listed g Injection site reaction includes the following MedDRA PTs: injection site reaction, injection site swelling, injection site pain, injection site mass, injection site erythema, injection site cellulitis, injection site rash, injection site induration, injection site abscess, injection site pruritus, injection site nodule, injected limb mobility decreased, injection site urticaria, injection site inflammation, injection site bruising, injection site infection, and injection site warmth.
h Rash includes the following MedDRA PTs: rash, rash generalised, rash erythematous, rash pruritic, rash maculo-papular, rash macular, rash vesicular, rash papular, rash morbilliform, and rash pustular. The number of reports of particular adverse events has changed over time ( Figure 6 ). The variation in reporting of ISRs is related to changes in the immunisation schedule for vaccines that are known to have higher rates of ISR, including DTPa-containing vaccines, 23vPPV and HPV vaccine. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 34, 35 Increases in reports of AEFI were largely associated with time periods when new vaccines were added to the NIP, or eligibility extended, in the reporting period, including: 7vPCV (2005) 
Severity of outcomes
The majority of reported adverse events in 2017 were defined as 'non-serious' (n=3,430, 88%). Twelve per cent (n=448) were defined as serious, an increase of 34% from 2016 ( Figure 1 ).
Three deaths were reported as temporally associated with receipt of vaccines in this reporting period.
• A 71 year old male died in early January 2017, a month after receiving a dose of the zoster vaccine. The person had chronic lymphocytic leukaemia, a contraindication to the live zoster vaccine. The cause of death was disseminated varicella-zoster virus (Oka strain) infection with meningoencephalitis and aspiration pneumonia resulting in death. This man's death was investigated by the TGA and a clear causal relationship with vaccination was found.
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• A 24-year old male who was on azathioprine and had recently commenced high dose corticosteroids for a serious medical condition was administered the live varicella vaccine. Over the subsequent two weeks he also received infliximab. He developed disseminated varicella-zoster virus infection (Oka strain) 19 days after vaccination and subsequently developed haemophagocytic lymphohistiocytosis (HLH) and died 3 months after varicella vaccination. This man's death was determined to be causally related to varicella vaccination.
• A 2-month old male with complex cardiac disease and cardiac surgery four times in first 6 weeks of life died following immunisation. Post-op progress was complicated by multiple cardiac issues, ventilator dependency, sepsis, high volume chylothoraces, steroid dependency and renal dysfunction. One day following vaccination (8 weeks scheduled vaccination) he developed left upper limb focal clonic seizures. He was treated for central nervous system infection but continued to deteriorate and died at 9 weeks of age. This child's death was considered to be due to complicated medical conditions and sequelae of surgery, coincidental to vaccination.
Furthermore, two miscarriages (spontaneous abortion) were reported in this period:
• A 36 year old female had an anembryonic pregnancy and a subsequent miscarriage. She had conceived a few days before having the influenza vaccine. No further details were available for this case.
• A 44 year old female was given the Fluarix Tetra vaccine in early pregnancy and developed vaginal spotting later on the day of vaccination. Miscarriage occurred 2 days later.
Additionally, two deaths were reported to TGA as vaccine failures, not effects of the vaccine.
• failure and septic shock. She was transferred to another hospital via ambulance but died en route. The patient tested positive for Influenza B (Phuket strain) found in the 2017 Fluarix Tetra. This was a report of vaccine failure.
• A 10 year old female developed Haemophilus influenzae type b (Hib) epiglottitis and died. She had been age-appropriately vaccinated with Hib vaccine (Comvax, MSD). This was a report of vaccine failure.
In summary, all deaths following immunisation reported to the TGA were investigated by the TGA and where relevant, other relevant authorities, based on the information received from reporters. A clear causal relationship with vaccination was found for two of the seven deaths. Disseminated VZV infection from Oka vaccine strain was causally associated with death in these two cases. The use of live attenuated VZVcontaining vaccines in people who are immunocompromised is contraindicated due to the risk of unchecked vaccine virus replication causing serious disease. 16, 36 One death was assessed as coincidental to vaccination and the two spontaneous abortions reported to TGA did not undergo a causality assessment. Spontaneous abortions are known to occur in 11-22% of all pregnancies. 37, 38 Two deaths were due to vaccine failure, not adverse events following immunisation. Vaccine effectiveness varies by vaccine type, as well as vaccine recipient and pathogen characteristics.
The TGA encourages all reporters to provide sufficient information to allow the TGA to assess any causal relationship between the administration of a vaccine and the adverse event reported.
Discussion
This report uses similar methodology to the previous four annual reports. 2, 15, 33, 39 Analysis using MedDRA preferred terms allows for clearer reporting of adverse events, but needs to be taken into account when comparing with data from annual reports prior to 2013.
In 2017, there was a 12% increase in the AEFI reporting rate compared with the previous year. This increase was mainly attributable to introduction of the booster dose of DTPa vaccine at 18 months of age in April 2016; zoster vaccine for those aged 70-79 years in November 2016; and state-funded meningococcal vaccination programs in 2017. There is usually an increase in reporting of adverse events when a new program or scheduled dose is rolled out, as immunisation providers are more likely to report milder, less serious AEFI for vaccines they are not as familiar with, or that are being given to a new population group. A reduction and stabilisation of reporting rates over time often occurs thereafter. 2, 4, 5, 7, 10, [12] [13] [14] [15] 33, 40 During this second year of implementation of the booster dose of DTPa, there were 376 AEFI reports, although the majority (93%) were not serious. There were 342 AEFI reports in adults who received zoster vaccine, although the majority (96%) were not serious.
Two deaths causally related to varicella zoster virus-containing (VZV) live attenuated vaccines, administered to immunocompromised adults who were contraindicated to receive them, occurred in 2017. One death was reported following Zostavax® vaccination in an immunocompromised adult. 36, 41 An immunocompromised 24-year old also died of disseminated Oka strain VZV infection associated with HLH and complicated inflammatory bowel disease following varicella vaccination. These live vaccines are contraindicated in immunocompromised people. 16 Overall, injection site reaction, pyrexia, rash, vomiting and pain were the most commonly reported reactions to the TGA in 2017. AEFI reporting rates for most individual vaccines in 2017 were similar to 2016. These findings are similar to nationally representative vaccine safety data from AusVaxSafety, which actively monitors the safety of pertussis, zoster, HPV and influenza vaccines in vaccinated people No safety signals were observed for these vaccines in 2017 in AusVaxSafety. 42 The majority of AEFI reports were non-serious events during 2017 and no new safety concerns arose during this period. However, two deaths occurred associated with the use of live VZVcontaining vaccines in immunocompromised persons, contraindicated to receive them. 36, 41 These are the first reports of Oka VZV vaccine strain associated death in Australia. A recently published global review reported that disseminated VZV disease after varicella and zoster vaccination was extremely rare and all cases from VZV vaccine (Oka strain) were in immmuncompromised people. 43 These unfortunate cases highlight the importance of ensuring that immunisation providers are aware of the important contraindications for the use of live attenuated vaccines, such as varicella, herpes zoster and yellow fever. Numerous additional communication and education activities targeted at immunisation providers have been undertaken to reinforce this. 44 
Conclusion
The number of reported AEFI increased in 2017 compared with 2016 though the majority were non-serious transient events. The data reported here are consistent with an overall high level of safety for vaccines used in Australia when used according to clinical recommendations contained within the Australian Immunisation Handbook. 16 
